Findings

What do systematic reviews say?

4,720 questions · 15,377 findings · 900 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3,865 · 25.1%GRADE not reported 2,291 · 14.9%Very low 3,875 · 25.2%Low 3,287 · 21.4%Moderate 1,681 · 10.9%High 378 · 2.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes

Adverse effects: abdominal mass · adults and children with cystic fibrosis

1 finding from 1 review

Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Summary of findings ‐ high‐dose pancreatic enzymes vs low‐dose pancreatic enzymes

Abdominal pain · adults and children with cystic fibrosis

1 finding from 1 review

Interventions for treating distal intestinal obstruction syndrome (DIOS) in cystic fibrosis 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Very low

Topical mydriatics vs intracameral mydriatics

Mean pupillary diameter—at the time the surgeon performs capsulorhexis (mm) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 757 participants
Low

Topical mydriatics vs intracameral mydriatics

AE: cystoid macular edema · patients undergoing cataract surgery

Topical mydriatics showed no clear difference in AE: cystoid macular edema compared with intracameral mydriatics (low certainty).

2 findings from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
RR 0.32 [0.01, 7.83]
1 study · 555 participants
Low
Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
RR 0.32 [0.01, 7.83]
1 study · 555 participants
Low

Topical mydriatics vs depot delivery systems

Mean pupillary diameter—at the time the surgeon performs capsulorhexis (mm) · patients undergoing cataract surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical mydriatics vs depot delivery systems

Mean pupillary diameter—at the beginning of cataract surgery (mm) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 324 participants
Low

Topical mydriatics vs depot delivery systems

Mean pupillary diameter—at the end of cataract surgery (mm) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 210 participants
Very low

Topical mydriatics vs depot delivery systems

Intraoperative surgical time—total intraoperative time (min) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 58 participants
Very low

Topical mydriatics vs depot delivery systems

AE: participant‐reported ocular discomfort—week 1 · patients undergoing cataract surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical mydriatics vs depot delivery systems

AE: participant‐reported ocular discomfort—month 1 · patients undergoing cataract surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical mydriatics vs depot delivery systems

AE: vitreous loss—any time point during or after surgery · patients undergoing cataract surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intracameral mydriatics vs depot delivery systems

Mean pupillary diameter—at the time the surgeon performs capsulorhexis (mm) · patients undergoing cataract surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Topical mydriatics vs intracameral mydriatics

Mean pupillary diameter—at the beginning of cataract surgery (mm) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 242 participants
Low

Intracameral mydriatics vs depot delivery systems

Mean pupillary diameter—at the beginning of cataract surgery (mm) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Intracameral mydriatics vs depot delivery systems

Mean pupillary diameter—at the end of cataract surgery (mm) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Intracameral mydriatics vs depot delivery systems

Intraoperative surgical time—total intraoperative time (min) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Intracameral mydriatics vs depot delivery systems

AE: participant‐reported ocular discomfort—week 1 · patients undergoing cataract surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intracameral mydriatics vs depot delivery systems

AE: participant‐reported ocular discomfort—month 1 · patients undergoing cataract surgery

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intracameral mydriatics vs depot delivery systems

Adverse events · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

Topical mydriatics vs intracameral mydriatics

Mean pupillary diameter—at the end of cataract surgery (mm) · patients undergoing cataract surgery

1 finding from 1 review

Pharmacologic interventions for mydriasis in cataract surgery 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 799 participants
Low